Poor environmental quality is associated with greater odds of an advanced stage prostate cancer at diagnosis, with a study finding the strongest associations for lower water, land, sociodemographic quality.
In the second-line treatment of patients advanced oesophageal cancer, the use of programmed cell death 1 (PD-1) inhibitors yields more favourable outcomes than chemotherapy across multiple patient subgroups, according to the results of a meta-analysis.
Temozolomide administered to patients with glioblastoma at full actual body weight dosing during the concurrent phase is necessary to achieve a median overall survival (OS) that is similar to that seen in a previous trial, according to a recent study.
The circulating levels of microRNA (miR)-146a is a potential noninvasive biomarker for the diagnosis and prognosis of acute lymphoblastic leukaemia (ALL) in both paediatric and adult patients, a recent study has found.
Prostate-specific antigen (PSA) screening was associated with similar decrease in incidence of advanced prostate cancer (PCa) among statin users vs nonusers, but less detection of low-grade localized tumours in the former than the latter — indicating that statin does not compromise the benefits of PSA-based screening while also conferring the benefit of less overdiagnosis of low-risk tumours.
Treatment with docetaxel appears beneficial in patients with low- and high-burden metastatic hormone-sensitive prostate cancer, a study has shown. However, no consistent differences for overall survival are seen in subgroup analyses as regards volume of metastatic disease.
Nivolumab is a promising therapy for patients with thymic epithelial tumours who have received multiple-line treatments, suggests a study. However, the high rate of severe toxicities specifies a need to find out a reliable marker to predict patients who will derive benefit or exhibit toxicity.